FIELD: biotechnology.
SUBSTANCE: invention concerns medicinal products based on recombinant human interferon alfa-2b without methionine for the treatment of children, including newborns and premature and pregnant women. The pharmaceutical composition is presented in the form of a gel, as an active substance it contains human recombinant methionine-free interferon alpha-2b and additional components selected from the group of substances that contribute to the restoration of the ciliated epithelium of the mucous membrane, absorption enhancers of medicinal substances and excipients that provide a stable pH, isotonicity and the preservation of the properties of the new dosage form during storage, the gel base.
EFFECT: medicinal product contains only components permitted in pediatric and obstetric practice and has high activity and high adhesive ability.
5 cl, 2 tbl, 7 ex
| Title | Year | Author | Number |
|---|---|---|---|
| PROLONGED INTERFERON SOLUTION | 2004 |
|
RU2270692C1 |
| IMMUNOCORRECTIVE AGENT FOR TREATING DISEASES OF VIRAL AETIOLOGY | 2007 |
|
RU2411039C2 |
| AGENT POSSESSING IMMUNOMODULATORY AND ANTIVIRAL ACTIVITY | 2015 |
|
RU2592201C1 |
| HYPOALLERGENIC MEDICINAL AGENT APPLIED FOR TREATMENT OF INFECTION-INFLAMMATORY DISEASES OF DIFFERENT AETIOLOGY | 2007 |
|
RU2326688C1 |
| MEDICINE WITH IMMUNE MODIFYING, ANTIVIRUS, ANTIBACTERIAL ANTIOXIDISING, MEMBRANE STABILISING, CARTILAGE AND CONNECTIVE TISSUE GROWTH STIMULATING EFFECT | 2007 |
|
RU2349339C1 |
| "VIFERON" APPLICATION FOR PREGNANT WOMEN WITH HPV INFECTION TO PREVENT PLACENTA INFECTION AND PLACENTAL INSUFFICIENCY | 2015 |
|
RU2620547C1 |
| PHARAMCEUTICAL AGENT FOR TREATMENT OF VIRAL AND DIFFERENT INFECTIONS | 2006 |
|
RU2323738C1 |
| AGENT FOR SEVERE INFECTIOUS DISEASES AND MIXED INFECTIONS | 2008 |
|
RU2366450C1 |
| STABILISED IMMUNE-CORRECTIVE DRUG VIFERON-FORTE FOR TREATING INFECTIOUS-INFLAMMATORY DISEASES | 2008 |
|
RU2381812C1 |
| RECTAL SUPPOSITORIES AND DEVICE FOR INTRODUCTION THEREOF | 1991 |
|
RU2024253C1 |
